China National Accord Medicines Corp Ltd

Sinopharm Accord released its 2026 interim report. Total operating revenue was 36.266 billion yuan, down 1.44% year on year, and net profit attributable to the parent company was 606 million yuan, down 8.97% year on year. Net cash flow from operating activities was negative 1.519 billion yuan, a decrease of 1.534 billion yuan compared with the same period last year. The company's asset-liability ratio was 54.55%, gross margin was 10.04%, return on equity was 3.21%, and diluted earnings per share was 0.99 yuan. The number of shareholders was 39,700, and the top ten shareholders held 62.06% of the total share capital.

Sinopharm Accord released its 2026 interim results flash. The company achieved total operating revenue of 36.266 billion yuan, down 1.44% year on year. Net profit attributable to the parent was about 606 million yuan, down 8.97% year on year. The distribution segment achieved operating revenue of 26.539 billion yuan, down 0.91% year on year, with net profit of 460 million yuan, down 4.56% year on year. The retail segment achieved operating revenue of 10.227 billion yuan, down 2.40% year on year, with the decline narrowing, and net profit of 13 million yuan, down 19.74% year on year.